Investigating the biology and treatment targets of infantile rhabdomyosarcoma

Understanding Infantile Rhabdomyosarcoma Biology and Therapeutic Targets

NIH-funded research Research Inst Nationwide Children's Hosp · NIH-10927267

This study is looking into a type of cancer called infantile rhabdomyosarcoma that affects young kids, and it's trying to find out how certain genes, especially one called VGLL2-NCOA2, might help us discover better treatments that are less harsh than the usual chemotherapy and surgery.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionResearch Inst Nationwide Children's Hosp NIH-funded
Lab location1 site (Columbus, United States)
Project IDNIH-10927267 on NIH RePORTER

What this research studies

This research focuses on understanding infantile rhabdomyosarcoma (RMS), an aggressive cancer that affects young children. The project aims to explore the genetic factors that contribute to this cancer, particularly a specific gene fusion known as VGLL2-NCOA2, which is linked to muscle development. By utilizing various models, including zebrafish and mouse models, as well as patient samples, the researchers hope to identify new therapeutic targets that could lead to more effective treatments. The ultimate goal is to improve treatment options beyond the current general chemotherapy and surgery methods, which often have severe side effects.

Who could benefit from this research

Good fit: Ideal candidates for this research are children under 11 years old diagnosed with infantile rhabdomyosarcoma.

Not a fit: Patients with other types of cancer or those over the age of 11 may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more targeted and effective treatments for infantile rhabdomyosarcoma, reducing the need for harsh chemotherapy and improving outcomes for young patients.

How similar studies have performed: While there has been significant research into rhabdomyosarcoma, this specific approach focusing on the VGLL2-NCOA2 fusion and its therapeutic implications is relatively novel.

Where this research is happening

Columbus, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.